NCT05197504View on ClinicalTrials.gov

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

CompletedOBSERVATIONAL

Enrollment

166

Participants

Timeline

Start Date

December 20, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

atezolizumab plus bevacizumab

1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks

Trial Locations (1)

13496

CHA Bundang Medical Center, Seongnam-si

All Listed Sponsors

lead

CHA University

OTHER

NCT05197504 - Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy | Biotech Hunter | Biotech Hunter